Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WO3979
- Development stage
- Phase 3
- Lead developer
- Dr August Wolff
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
WO3979 is an investigational topical formulation containing glycopyrronium bromide, developed by Dr. August Wolff GmbH & Co. KG Arzneimittel. It is being evaluated for the treatment of axillary hyperhidrosis, a condition characterized by excessive underarm sweating. Glycopyrronium bromide acts as an anticholinergic agent, blocking muscarinic receptors to reduce sweat production.
- Brand names
- RobinulSeebriCuvposaQbrexzaGlycate
- Other names
- GPB topical formulation
02
Targets
M1 (Muscarinic acetylcholine receptor M1)CHRM2 (M2)CHRM3 (M3)CHRM4 (M4)CHRM5 (M5)
Beyond the preview
Go deeper on WO3979.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WO3979.